INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 285 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,125,248 | -29.3% | 21,602 | -14.1% | 0.03% | -28.3% |
Q2 2023 | $1,591,674 | +11.7% | 25,137 | -4.5% | 0.05% | +4.5% |
Q1 2023 | $1,424,686 | +87036.8% | 26,310 | -14.9% | 0.04% | -13.7% |
Q4 2022 | $1,635 | -99.9% | 30,902 | -69.6% | 0.05% | -37.8% |
Q3 2022 | $2,365,363 | -20.3% | 101,552 | +95.3% | 0.08% | -18.0% |
Q2 2022 | $2,968,000 | – | 51,997 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |